LENZ Therapeutics, Inc. LENZ 深 沪
等待开盘 06-26 09:30:00 美东时间
5.355
-0.215
-3.86%
华盛通- 最 高6.1827
- 今 开5.63
- 成交量 29.82万股
- 最 低 5.3475
- 昨 收 5.57
- 总市值 0
- 52周最高 50.19
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 5.3475
- 委 比 1.45%
- 总股本 --
- 历史最高 50.19
- 量 比 0.62
- 振 幅 14.99%
- 历史最低 1.10
- 每 手 1
- 风险率 12.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst
LENZ Therapeutics partners with Arrotex to commercialize VIZZ in Australia and New Zealand as analysts remain focused on U.S. growth.
06-25 01:41
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug
FDA approved Tenpoint's Yuvezzi eye drop for presbyopia, adding competition for LENZ's VIZZ as analysts say the recent stock drop may be overdone and see blockbuster potential ahead.
01-31 02:02
LENZ Therapeutics to Present at Upcoming Investor Conferences
LENZ Therapeutics announced its management will participate in three upcoming investor conferences: William Blair 45th Annual Growth Stock Conference on June 3 in Chicago, Jefferies Global Healthcare Conference on June 4-5 in New York, and Goldman Sachs 46th Annual Global Healthcare Conference on June 9 in Miami. The company, focusing on developing an aceclidine-based eye drop for presbyopia, is awaiting FDA approval for its LNZ100 product with a PDUFA date of August 8, 2025.
2025-05-27 12:00
Piper Sandler Maintains Overweight on LENZ Therapeutics, Maintains $36 Price Target
Piper Sandler analyst Joseph Catanzaro maintains LENZ Therapeutics (NASDAQ:LENZ) with a Overweight and maintains $36 price target.
2024-08-16 01:59
